跳至主要内容
临床试验/NCT05730907
NCT05730907招募中不适用

Efficacy and Clinical Outcomes of Levosimendan in E-CPR

Hamad Medical Corporation1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年2月20日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
1
主要终点
Survival to hospital discharge

研究概览

简要总结

Treatment of refractory cardiac arrest requiring cardiopulmonary resuscitation (CPR) may be augmented with Extracorporeal membrane oxygenation (ECMO) to re-establish perfusion in the absence of return of spontaneous circulation. Literature has demonstrated that ECMO initiated during advanced cardiopulmonary life support may confer superior survival rates with acceptable survival and a relatively low incidence of significant neurologic impairment. Levosimendan has not been investigated in patients with cardiac arrest who underwent Extracorporeal CPR (E-CPR). The current study aims to examine whether levosimendan use in the aforementioned patient population could improve survival and ECMO parameters.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Survival to hospital discharge

时间窗: 6 months

Survival to hospital discharge with good neurological outcomes

次要结局

  • Survival to decannulation(6 months)
  • long term survival(6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验